Literature DB >> 15159464

Use of narcotic analgesics in the emergency department treatment of migraine headache.

I Colman1, A Rothney, S C Wright, B Zilkalns, B H Rowe.   

Abstract

OBJECTIVE: Treatment of acute migraine headache with narcotics is potentially ineffective and may lead to abuse. The authors examined the treatment practice variation across five linked EDs in one Canadian center, focusing on the use of narcotic analgesics and factors associated with their use.
METHODS: Five hundred acute migraine headache patient charts were randomly selected from five Canadian EDs. Charts underwent a structured review to determine medication use. Data were analyzed, comparing those who received narcotics as first-line treatment with those who did not, using chi(2) and t-tests and logistic regression.
RESULTS: The majority of patients (59.6%) received narcotics as first-line treatment. Numerous factors were associated with first-line narcotic treatment. Having taken antiheadache medications prior to ED presentation (odds ratio [OR]: 2.63; 95% CI: 1.53, 4.51) and hospital of presentation being other than Hospital A (e.g., Hospital D, OR: 6.32; 95% CI: 2.76, 14.46) increased the odds of receiving first-line narcotics. Having received a more urgent triage score (OR: 0.4; 95% CI: 0.24, 0.65) or having a longer duration of headache (OR: 0.994; 95% CI: 0.99, 0.99) decreased the odds of receiving first-line narcotics.
CONCLUSIONS: Acute migraine management in these EDs does not meet current consensus guidelines. Factors associated with narcotic use are predictable, and a concerted effort to replace narcotics with more evidence-based first-line treatments is needed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15159464     DOI: 10.1212/01.wnl.0000127304.91605.ba

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  26 in total

1.  Comparison of parenteral treatments of acute primary headache in a large academic emergency department cohort.

Authors:  Lucas H McCarthy; Robert P Cowan
Journal:  Cephalalgia       Date:  2014-11-03       Impact factor: 6.292

2.  The diagnosis and treatment of chronic migraine: the case for daily scheduled opioid treatment in chronic headache.

Authors:  Iraj Derakhshan
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

3.  [Acceptance of recommendations and guidelines for pain therapy with opioids].

Authors:  Hardo Sorgatz
Journal:  Schmerz       Date:  2005-10       Impact factor: 1.107

Review 4.  Diagnosis and management of the primary headache disorders in the emergency department setting.

Authors:  Benjamin Wolkin Friedman; Brian Mitchell Grosberg
Journal:  Emerg Med Clin North Am       Date:  2009-02       Impact factor: 2.264

5.  [The role of opioids in the treatment of primary headache disorders].

Authors:  A Totzeck; C Gaul
Journal:  Schmerz       Date:  2014-04       Impact factor: 1.107

6.  Treatment of acute migraine in the emergency department.

Authors:  Saurabh Gupta; Richard Oosthuizen; Simon Pulfrey
Journal:  Can Fam Physician       Date:  2014-01       Impact factor: 3.275

7.  Examination of migraine management in emergency departments.

Authors:  Satnam Singh Nijjar; Leah Pink; Allan S Gordon
Journal:  Pain Res Manag       Date:  2011 May-Jun       Impact factor: 3.037

Review 8.  Management of primary headaches in adult Emergency Departments: a literature review, the Parma ED experience and a therapy flow chart proposal.

Authors:  Paola Torelli; Valentina Campana; Gianfranco Cervellin; Gian Camillo Manzoni
Journal:  Neurol Sci       Date:  2010-07-08       Impact factor: 3.307

9.  Use of the emergency department for severe headache. A population-based study.

Authors:  Benjamin W Friedman; Daniel Serrano; Michael Reed; Merle Diamond; Richard B Lipton
Journal:  Headache       Date:  2008-11-25       Impact factor: 5.887

Review 10.  Treatment of pediatric migraine in the emergency room.

Authors:  Amy A Gelfand; Peter J Goadsby
Journal:  Pediatr Neurol       Date:  2012-10       Impact factor: 3.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.